Alector Financials
ALEC Stock | USD 3.94 0.18 4.79% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0302 | 0.0568 |
|
| |||||
Current Ratio | 3.02 | 3.1796 |
|
|
Investors should never underestimate Alector's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Alector's cash flow, debt, and profitability to make informed and accurate decisions about investing in Alector.
Net Income |
|
Alector | Select Account or Indicator |
Understanding current and past Alector Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alector's financial statements are interrelated, with each one affecting the others. For example, an increase in Alector's assets may result in an increase in income on the income statement.
Please note, the presentation of Alector's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alector's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alector's management manipulating its earnings.
Alector Stock Summary
Alector competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Alector operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 269 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0144421072 |
CUSIP | 014442107 |
Location | California; U.S.A |
Business Address | 131 Oyster Point |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.alector.com |
Phone | 415 231 5660 |
Currency | USD - US Dollar |
Alector Key Financial Ratios
Return On Equity | -1.13 | ||||
Profit Margin | (2.58) % | ||||
Operating Margin | (3.01) % | ||||
Price To Sales | 6.27 X | ||||
Revenue | 97.06 M |
Alector Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 421.9M | 488.3M | 814.7M | 787.6M | 621.8M | 513.3M | |
Other Current Liab | (5.2M) | 26.2M | 28.4M | 33.3M | 74.3M | 78.0M | |
Other Liab | 123.7M | 108.9M | 334.6M | 444.1M | 510.7M | 536.3M | |
Net Tangible Assets | 194.7M | 267.5M | 300.7M | 214.4M | 246.6M | 126.2M | |
Net Debt | (41.6M) | 1.3M | (281.6M) | (111.0M) | (35.6M) | (37.4M) | |
Retained Earnings | (219.8M) | (410.0M) | (446.4M) | (579.7M) | (710.1M) | (674.6M) | |
Accounts Payable | 278K | 3.0M | 4.7M | 4.2M | 3.8M | 2.5M | |
Cash | 89.6M | 50.0M | 329.2M | 154.3M | 74.6M | 116.4M | |
Other Assets | 2.1M | 4.1M | 7.0M | 7.9M | 9.1M | 9.5M | |
Net Receivables | 200.2M | 0.0 | 7.4M | 2.6M | 2.3M | 2.2M | |
Capital Surpluse | 17.1M | 414.4M | 677.0M | 748.0M | 860.2M | 903.3M | |
Other Current Assets | 4.4M | 16.4M | 7.1M | 11.0M | 16.9M | 17.8M | |
Total Liab | 227.2M | 220.7M | 513.9M | 573.2M | 487.7M | 384.4M | |
Total Current Assets | 357.4M | 421.5M | 749.7M | 726.4M | 565.8M | 467.3M | |
Net Invested Capital | 194.7M | 267.5M | 300.7M | 214.4M | 134.2M | 151.2M | |
Net Working Capital | 295.5M | 353.4M | 610.2M | 632.6M | 387.9M | 429.1M | |
Short Term Debt | 6.6M | 15.0M | 15.6M | 8.1M | 16.9M | 12.9M |
Alector Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 6.6M | 2.4M | 7.4M | (4.8M) | (2.6M) | (2.5M) | |
Investments | (33.6M) | (100.0M) | (46.4M) | (159.0M) | 102.2M | 107.3M | |
Change In Cash | 24.2M | (39.7M) | 279.2M | (174.8M) | (79.7M) | (75.7M) | |
Free Cash Flow | (114.6M) | (171.8M) | 295.3M | (24.4M) | (186.5M) | (177.2M) | |
Depreciation | 5.6M | 7.3M | 8.3M | 8.5M | 8.8M | 5.6M | |
Capital Expenditures | 15.3M | 5.0M | 3.2M | 4.1M | 2.4M | 2.3M | |
Net Income | (105.4M) | (190.2M) | (36.3M) | (133.3M) | (130.4M) | (136.9M) | |
End Period Cash Flow | 91.1M | 51.4M | 330.6M | 155.8M | 76.1M | 117.6M | |
Change To Netincome | 16.3M | 30.6M | 40.8M | 45.0M | 51.7M | 54.3M | |
Other Non Cash Items | (3.5M) | 929K | 2.1M | (1.2M) | (15.3M) | (16.0M) |
Alector Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alector's current stock value. Our valuation model uses many indicators to compare Alector value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alector competition to find correlations between indicators driving Alector's intrinsic value. More Info.Alector is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . At present, Alector's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alector's earnings, one of the primary drivers of an investment's value.Alector Systematic Risk
Alector's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alector volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Alector correlated with the market. If Beta is less than 0 Alector generally moves in the opposite direction as compared to the market. If Alector Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alector is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alector is generally in the same direction as the market. If Beta > 1 Alector moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Alector Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alector's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Alector growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Alector November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alector help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alector. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alector based on widely used predictive technical indicators. In general, we focus on analyzing Alector Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alector's daily price indicators and compare them against related drivers.
Information Ratio | (0.07) | |||
Maximum Drawdown | 26.6 | |||
Value At Risk | (7.89) | |||
Potential Upside | 8.66 |
Complementary Tools for Alector Stock analysis
When running Alector's price analysis, check to measure Alector's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alector is operating at the current time. Most of Alector's value examination focuses on studying past and present price action to predict the probability of Alector's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alector's price. Additionally, you may evaluate how the addition of Alector to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |